Muse Bio
Muse.Bio
- Business Model
- B2B
- Website
- mycells.bio
- Total Funding
- $24.1M
- Last Round
- $1.1M Pre-SeedFeb 2025
- Rounds
- 2
About
Muse Bio is a stem cell research company studying menstrual blood-derived stem cells for regenerative medicine and therapeutic development.
Summary
Muse Bio is a Biotech company. It has raised $24.1M in total across 2 rounds, most recently a $1.1M Pre-Seed round in Feb 2025. Investors include Draper Associates, Venrock and Foresite Capital.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Feb 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company